Peter Hinderlie

1.2k total citations
23 papers, 878 citations indexed

About

Peter Hinderlie is a scholar working on Immunology, Oncology and Hematology. According to data from OpenAlex, Peter Hinderlie has authored 23 papers receiving a total of 878 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Immunology, 13 papers in Oncology and 3 papers in Hematology. Recurrent topics in Peter Hinderlie's work include Immune Cell Function and Interaction (23 papers), CAR-T cell therapy research (10 papers) and T-cell and B-cell Immunology (7 papers). Peter Hinderlie is often cited by papers focused on Immune Cell Function and Interaction (23 papers), CAR-T cell therapy research (10 papers) and T-cell and B-cell Immunology (7 papers). Peter Hinderlie collaborates with scholars based in United States, Sweden and Netherlands. Peter Hinderlie's co-authors include Jeffrey S. Miller, Martin Felices, Melissa A. Geller, Laura E. Bendzick, Daniel A. Vallera, Bruce R. Blazar, Behiye Kodal, Alexander J. Lenvik, Ron McElmurry and Sarah Cooley and has published in prestigious journals such as The Journal of Experimental Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Peter Hinderlie

23 papers receiving 867 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Peter Hinderlie United States 14 769 531 96 90 74 23 878
Alexander J. Lenvik United States 7 801 1.0× 664 1.3× 109 1.1× 149 1.7× 134 1.8× 15 937
Cécile Bonnafous France 13 740 1.0× 580 1.1× 129 1.3× 113 1.3× 123 1.7× 34 1.0k
Julie Gertner-Dardenne France 10 542 0.7× 416 0.8× 73 0.8× 58 0.6× 38 0.5× 17 727
Erik Ames United States 15 740 1.0× 488 0.9× 178 1.9× 160 1.8× 29 0.4× 26 965
Hilde Omholt Norway 6 579 0.8× 384 0.7× 131 1.4× 52 0.6× 44 0.6× 7 689
Huaijian Guo Canada 8 492 0.6× 236 0.4× 166 1.7× 148 1.6× 55 0.7× 11 661
Tsin Yee Tai Australia 12 593 0.8× 275 0.5× 263 2.7× 113 1.3× 62 0.8× 21 724
Ilia N. Buhtoiarov United States 15 614 0.8× 409 0.8× 164 1.7× 31 0.3× 100 1.4× 30 812
Dawn K. Schirm United States 8 588 0.8× 264 0.5× 76 0.8× 169 1.9× 33 0.4× 8 711
Mario‐Ernesto Cruz‐Munoz Canada 9 615 0.8× 220 0.4× 111 1.2× 180 2.0× 38 0.5× 9 750

Countries citing papers authored by Peter Hinderlie

Since Specialization
Citations

This map shows the geographic impact of Peter Hinderlie's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Hinderlie with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Hinderlie more than expected).

Fields of papers citing papers by Peter Hinderlie

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Hinderlie. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Hinderlie. The network helps show where Peter Hinderlie may publish in the future.

Co-authorship network of co-authors of Peter Hinderlie

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Hinderlie. A scholar is included among the top collaborators of Peter Hinderlie based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Hinderlie. Peter Hinderlie is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Zorko, Nicholas A., Peter Hinderlie, Amanda J. Russell, et al.. (2024). Effect of camelid B7-H3 tri-specific killer engagers on natural killer cells in patients with prostate cancer.. Journal of Clinical Oncology. 42(4_suppl). 155–155. 1 indexed citations
3.
Felices, Martin, Laura E. Bendzick, Behiye Kodal, et al.. (2023). Reverse Translation Identifies the Synergistic Role of Immune Checkpoint Blockade and IL15 to Enhance Immunotherapy of Ovarian Cancer. Cancer Immunology Research. 11(5). 674–686. 8 indexed citations
4.
Kennedy, Philippa R, Daniel A. Vallera, Behiye Kodal, et al.. (2023). A tri-specific killer engager against mesothelin targets NK cells towards lung cancer. Frontiers in Immunology. 14. 1060905–1060905. 14 indexed citations
5.
Davis, Zachary, Frank Cichocki, Martin Felices, et al.. (2022). A Novel Dual-Antigen Targeting Approach Enables Off-the-Shelf CAR NK Cells to Effectively Recognize and Eliminate the Heterogenous Population Associated with AML. Blood. 140(Supplement 1). 10288–10289. 7 indexed citations
6.
Schirm, Dawn K., et al.. (2022). Balanced engagement of activating and inhibitory receptors mitigates human NK cell exhaustion. JCI Insight. 7(15). 30 indexed citations
7.
Kamiński, Michał F., Laura E. Bendzick, Behiye Kodal, et al.. (2022). TEM8 Tri-specific Killer Engager binds both tumor and tumor stroma to specifically engage natural killer cell anti-tumor activity. Journal for ImmunoTherapy of Cancer. 10(9). e004725–e004725. 14 indexed citations
8.
Davis, Zachary, Martin Felices, Todd Lenvik, et al.. (2021). Low-density PD-1 expression on resting human natural killer cells is functional and upregulated after transplantation. Blood Advances. 5(4). 1069–1080. 26 indexed citations
9.
Zorko, Nicholas A., Martin Felices, Aimee Merino, et al.. (2021). 126P Novel B7-H3 targeting dual nanobody NK cell engagers display robust activity against a broad spectrum of solid and hematologic malignancies. Annals of Oncology. 32. S1433–S1433. 4 indexed citations
10.
Vallera, Daniel A., Behiye Kodal, Peter Hinderlie, et al.. (2021). A HER2 Tri-Specific NK Cell Engager Mediates Efficient Targeting of Human Ovarian Cancer. Cancers. 13(16). 3994–3994. 37 indexed citations
11.
12.
Felices, Martin, Todd Lenvik, Behiye Kodal, et al.. (2020). Potent Cytolytic Activity and Specific IL15 Delivery in a Second-Generation Trispecific Killer Engager. Cancer Immunology Research. 8(9). 1139–1149. 51 indexed citations
13.
Hinderlie, Peter, et al.. (2020). 675 Oxygen concentration alters natural killer cell phenotype and function in the solid tumor microenvironment. SHILAP Revista de lepidopterología. A405–A406. 2 indexed citations
14.
Vallera, Daniel A., Soldano Ferrone, Behiye Kodal, et al.. (2020). NK-Cell-Mediated Targeting of Various Solid Tumors Using a B7-H3 Tri-Specific Killer Engager In Vitro and In Vivo. Cancers. 12(9). 2659–2659. 71 indexed citations
15.
Felices, Martin, Laura E. Bendzick, Caitlin Ryan, et al.. (2019). Cytokine-induced memory-like natural killer cells have enhanced function, proliferation, and in vivo expansion against ovarian cancer cells. Gynecologic Oncology. 153(1). 149–157. 82 indexed citations
16.
Davis, Zachary, Martin Felices, Todd Lenvik, et al.. (2019). PD-1 Is Expressed at Low Levels on All Peripheral Blood Natural Killer Cells but Is a Significant Suppressor of NK Function Against PD-1 Ligand Expressing Tumor Targets. Blood. 134(Supplement_1). 621–621. 4 indexed citations
17.
Felices, Martin, Behiye Kodal, Peter Hinderlie, et al.. (2019). Novel CD19-targeted TriKE restores NK cell function and proliferative capacity in CLL. Blood Advances. 3(6). 897–907. 70 indexed citations
18.
Felices, Martin, Alexander J. Lenvik, Ron McElmurry, et al.. (2018). Continuous treatment with IL-15 exhausts human NK cells via a metabolic defect. JCI Insight. 3(3). 184 indexed citations
19.
Witte, Moniek A. de, Dhifaf Sarhan, Zachary Davis, et al.. (2018). Early Reconstitution of NK and γδ T Cells and Its Implication for the Design of Post-Transplant Immunotherapy. Biology of Blood and Marrow Transplantation. 24(6). 1152–1162. 47 indexed citations
20.
Cichocki, Frank, Cheng‐Ying Wu, Bin Zhang, et al.. (2018). ARID5B regulates metabolic programming in human adaptive NK cells. The Journal of Experimental Medicine. 215(9). 2379–2395. 95 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alexander J. Lenvik Breakdown of academic impact, for papers by Cécile Bonnafous Breakdown of academic impact, for papers by Julie Gertner-Dardenne Breakdown of academic impact, for papers by Erik Ames Breakdown of academic impact, for papers by Hilde Omholt Breakdown of academic impact, for papers by Huaijian Guo Breakdown of academic impact, for papers by Tsin Yee Tai Breakdown of academic impact, for papers by Ilia N. Buhtoiarov Breakdown of academic impact, for papers by Dawn K. Schirm Breakdown of academic impact, for papers by Mario‐Ernesto Cruz‐Munoz
Rankless by CCL
2026